and with severe community-acquired pneumonia. 8 Both experimental 9, 10 and clinical 11, 12 data suggest that corticosteroid use may decrease the occurrence and severity of nosocomial pneumonia in patients treated in intensive care units (ICUs).
Persistent systemic inflammatory response syndrome was predictive of nosocomial infection in trauma patients. 13, 14 Trauma-related corticosteroid insufficiency was also correlated with systemic inflammatory response syndrome. 15 It has been suggested that hydrocortisone attenuates the overwhelming inflammatory response without immunosuppression, restoring an adequate immune response to infection. 10 We postulated that treatment with stress-dose levels of hydrocortisone would diminish the prevalence of hospital-acquired pneumonia, the first cause of infection in trauma patients.
METHODS

Study Design
This multicenter, randomized, doubleblind, parallel, placebo-controlled study was approved by the institutional review board of Angers, France. Patients were enrolled from November 15, 2006 , to August 4, 2009 , when recruitment was completed at the 7 participating French ICUs. Patients were enrolled after a next-of-kin provided written informed consent. Retrospective consent, when available, was obtained from patients. The authors designed the study, but data were gathered and analyzed by an independent monitoring board.
Patients with multiple trauma who were older than 15 years 3 months and expected to require mechanical ventilation for more than 48 hours were included in the study. Those with previous adrenal insufficiency, previous immunosuppression (for clinical definitions, see eAppendix available at http: //www.jama.com), treatment with corticosteroids within the last 6 months, or were pregnant were excluded.
Multiple trauma was defined as having 2 or more traumatic injuries and an injury severity score higher than 15 . Severe TBI was defined as a Glasgow Coma Scale score of less than or equal to 8 after initial care. 16 Corticosteroid insufficiency was defined as basal cortisolemia level lower than 15 µg/dL (to convert to nanomoles per liter multiply by 27.588) 17 or a maximal increase in the cortisol level lower than 9 µg/dL in the 60 minutes following a short corticotropin test. 6, 7 Pneumonia was considered when at least 2 signs (body temperature Ͼ38°C; leukocytosis Ͼ12 000/mL, or leukopenia Ͻ4000/mL; purulent pulmonary secretions) associated with the appearance of a new infiltrate were present or when change occurred in an existing infiltrate on chest x-ray. [18] [19] [20] The diagnosis needed to be confirmed by a lower respiratory tract sample using a quantitative culture with a predefined positive threshold of 10 4 colony-forming units per milliliter (CFU/mL) for a bronchoalveolar lavage or nonbronchoscopic sample and 10 3 CFU/mL for a protected specimen brush. Hospitalacquired pneumonia was defined as pneumonia that occurs 48 hours after admission that had not been incubating at the time of admission. The definitions of other infections as well as organ failure are provided as supplemental material (eAppendix). Patients were randomized in a 1:1 ratio in fixed blocks of 4 and stratified according to the treatment center, the presence of severe TBI, and injury severity score higher than 30 by a computerized number generator list provided by a statistician not involved in the determination of eligibility or in the assessment of outcomes. All assignments were made through a central randomization center. In each center, an unblinded pharmacist who was not involved in the determination of eligibility or in the assessment of outcomes prepared the study drug. Patients, investigators, and members of the monitoring board and medical and nursing staff were unaware of the patients' treatment assignment.
Study drug infusion began within 36 hours of the trauma onset, immediately after the completion of a short corticotropin test. Hydrocortisone hemisuccinate (Upjohn, Serb laboratory, Paris, France) and placebo were prepared immediately before use in a syringe containing 48 mL of saline isotonic solution. In addition to standard of care, the study drugs were continuously administered intravenously as follows: 200 mg/d for 5 days, 100 mg on day 6, and 50 mg on day 7 for patients with corticosteroid insufficiency. After receiving the results of the short corticotropin test (in the first 48 hours following inclusion), the treatment was stopped if patients had an adapted corticosteroid function.
Each patient's general characteristics including demographics, injury severity score and abbreviated injury score, fluid infusions, vasopressors, antibiotic prophylaxis, etomidate use, surgery, infections, organ failures, length of ventilatory support, and ICU hospitalization and death at day 28 were recorded.
Immediately before beginning the treatment, but at least 8 hours after a bolus injection of etomidate, 6 a short corticotropin test was performed: cortisolemia before and 30 and 60 minutes after an intravenous bolus of 0.25 mg of corticotropin (Novartis, Rueil-Malmaison, France). In patients with corticosteroid insufficiency, a second short corticotropin test was performed 24 hours after the end of treatment.
During the 28-day period after randomization, clinical assessments were performed twice a day in the ICU. Methods to enhance the quality of measurements included holding triannual telephone contact with investigators, sending e-mails, and conducting random quality assurance evaluations.
The study's primary outcome was occurrence of hospital-acquired pneumonia within 28 days of randomization. The secondary outcomes were duration of mechanical ventilation and length of ICU stay, rates of death, other infections, and organ failures, and duration of vasopressor support on day 28. Safety was assessed by recording adverse events.
Modifiable risk factors of hospitalacquired pneumonia 18 were prospectively recorded (eTable 1). Clinical HYDROCORTISONE FOR PATIENTS WITH MULTIPLE TRAUMA evaluation for diagnosis of pneumonia was performed twice a day in the ICU. A chest x-ray was taken as soon as pneumonia was suspected after clinical examination. A culture sample was collected immediately when radiographic infiltrates and antibiotic therapy was not modified.
Statistical Analysis
After verifying that the cumulative probability of hospital-acquired pneumonia on day 28 was significantly decreased in the hydrocortisone group compared with the placebo group using a stratified log-rank test (test initially planned for the primary end point), we decided a posteriori to perform complementary sensitivity analyses with an adjustment for etomidate use. The final a posteriori primary analysis consisted of evaluating the effect of hydrocortisone on the primary outcome (ie, pneumonia within 28 days), with adjustment by means of a Cox multivariate proportional hazards model that included 3 predefined covariates: the center, TBI (presence or absence), and the injury severity score (Յ30 or Ͼ30). Corresponding hazard ratios (HRs) along with their 95% confidence intervals (CIs) were reported. If a significant difference was confirmed for the primary end point, then subgroup analysis for TBI (presence or absence) was performed. The hierarchical testing procedure allowed us to control the family-wise type I error rate. A second complementary analysis was a priori planned considering mortality as part of the outcome (composite outcome). We also reported the crude KaplanMeier estimator at day 28. Because the randomization process came before the corticotropin test, an intention-totreat analysis (ITT) that includes the whole population was first performed followed by a modified ITT for patients with corticosteroid insufficiency.
For the power calculation, we a priori defined that patients with corticosteroid insufficiency would be treated, whereas treatment would be stopped for patients with appropriate corticosteroid function. The power calculation was performed for comparison between the hydrocortisone and placebo groups in patients with corticosteroid insufficiency. The sample size needed to detect an absolute decrease in pneumonia incidence of 20% was 45 patients in each group, assuming a basal rate of 50% 2-4 in a 2-sided test performed with a statistical power of 80% and an ␣ risk of .05. Assuming a rate of 50% of corticosteroid insufficiency, 15, 17, 21, 22 180 patients (45 patients in each group, and 90 patients with normal corticosteroid function who were untreated) were needed. After inclusion of the first 75 patients, an a priori intermediate analysis using the O'Brien and Fleming method for ␣ risk spending was used (P=.005 and P=.048 for the first and final analysis, respectively) and data showed that the incidence of corticosteroid insufficiency reached 70%. The sample size needed to ensure that the initial power was therefore achieved, and the study was stopped after enrolling 150 patients. Surgical procedure prior to study inclusion Duration of initial surgical procedure, median (IQR), h 
RESULTS
Patients
Patients were treated in level I trauma centers according to the Advanced Trauma Life Support principles. Of the 150 patients included, 1 patient was excluded because consent was withdrawn; the 149 remaining patients were analyzed (FIGURE 1). All patients were intubated prior to randomization. One hundred thirteen patients (76%) had corticosteroid insufficiency (56 in the hydrocortisone group and 57 in the placebo group), and 36 patients (24%) had reached normal corticosteroid function (Figure 1) FIGURE 2) . The Kaplan-Meier estimator at day 28 was 36.6% in the hydrocortisone group and 51.6% in the placebo group, with an absolute diminution in the hydrocortisone group of −15% (95% CI, −30.9% to 0.9%; P=.08).
There was no difference between groups in terms of modifiable risk factors of hospital-acquired pneumonia or in terms of pathogens involved (eTable 1 and eTable 2 available at http://www .jama.com). Considering mortality as part of the outcome (composite outcome), the difference between the 2 groups remained significant (HR, 0.56; 95% CI, 0.34-0.92; P = .02). The second analysis was adjusted for etomidate, and the HR for hospital-acquired pneumonia in the hydrocortisone group was 0.55 (95% CI, 0.32-0.93; P=.03).
The ITT analysis showed a significant difference between placebo and hydrocortisone group. The planned modified ITT analysis was performed using data of patients with corticosteroid insufficiency. Figure 2 ). The Kaplan-Meier estimator at day 28 was 37.1% in the hydrocortisone group and 54.4% in the pla- (13) 25 ( Abbreviations: ALI, acute lung injury; ARDS, acute respiratory distress syndrome; CI, confidence interval ; ICU, intensive care unit; IQR, interquartile range. Blank cells for P values and 95% CIs indicate that there were too few patients for calculations. For the glucocorticoid function, statistical analysis was not performed due to a lack of power. a Secondary outcomes were evaluated on day 28 (unless otherwise stated). b Calculated from Cox regression analysis. c The absolute difference was calculated as (hydrocortisone − placebo) and expressed as absolute value (95% CI). d Glucocorticoid function was not assessed on day 8 for patients with adapted corticosteroid function. e Glucocorticoid function was assessed for 40 patients in the hydrocortisone group and 51 patients in the placebo group.
HYDROCORTISONE FOR PATIENTS WITH MULTIPLE TRAUMA cebo group, with an absolute diminution in the hydrocortisone group of −17.3% (95% CI, −35.6% to 0.9%; P=.07). There was no difference between groups in terms of modifiable risk factors of hospital-acquired pneumonia or in terms of pathogens involved (eTable 1 and eTable 2). Considering mortality as part of the outcome (composite outcome), the HR in the hydrocortisone group compared with the placebo was 0.56 (95% CI, 0.31-1.00; P=.049). The second analysis was adjusted for etomidate, and the HR for hospital-acquired pneumonia with hydrocortisone was 0.48 (95% CI, 0.26-0.90; P=.02).
Among patients with corticosteroid insufficiency presenting with TBI, 13 of 32 (40.6%) in the hydrocortisone group and 25 of 35 (71.4%) in the placebo group developed hospitalacquired pneumonia at 28 days (HR, 0.36; 95% CI, 0.17-0.74). The test for interaction between treatment group and TBI subgroup was not significant (P for interaction= .12; FIGURE 3).
Of the 17 patients with appropriate corticosteroid function treated with hydrocortisone, 6 (35.3%) and 8 of 19 (42.1%) in the placebo group developed hospital-acquired pneumonia at 28 days (HR, 0.82; 95% CI, 0.23-2.93; P = .76; eFigure 1). The short exposure to treatment did not alter the outcomes for patients with an adapted corticosteroid function (eFigure 2 and eTable 4).
Secondary Outcomes
In the entire population, the HR for weaning from mechanical ventilation in the hydrocortisone group compared with the placebo was 1.71 (95% CI, 1.20-2.44; P =.003; FIGURE 4). The mean (SD) of mechanical ventilationfree days was 16 (8) days in the hydrocortisone group and 12 (9) days in the placebo group, with a mean absolute increase in the hydrocortisone group of 4 days (95% CI, 2-7; P=.001; TABLE 2). Three of 73 patients (4.1%) in the hydrocortisone group and 11 of 76 patients (14.5%) in the placebo group developed an acute lung injury or an acute respiratory distress syndrome (ARDS), with an absolute reduction of −10% (95% CI, −19% to −1%; P=.04; Table 2 ). The mean (SD) length of ICU stay was 18 (15) days in the hydrocortisone group and 24 (16) days in the placebo group, with a mean absolute reduction in the hydrocortisone group of −6 days (95% CI, −11 to −1; P = .03; Table 2 ). No difference was observed between the study groups regarding other outcomes (Table 2) .
In patients with corticosteroid insufficiency, the HR for weaning from mechanical ventilation in the hydrocortisone group compared with the placebo group was 1.90 (95% CI, 1.25-2.89; PϽ.001; Figure 4 ). The mean (SD) mechanical ventilation−free days was 16 (10) days in the hydrocortisone group and 10 (12) days in the placebo group, with a mean absolute increase in the hydrocortisone group of 6 days (95% CI, 2-11; PϽ.001; Table 2 ). Three of 56 patients (5.7%) in the hydrocortisone group and 8 of 57 patients (14%) in the placebo group developed an acute lung injury or acute respiratory distress syndome, with a mean absolute reduction in the hydrocortisone group of −8% (95% CI, −19% to 3%; P=.17; Table 2 ). The mean (SD) length of ICU stay was 17 (13) days in the hydrocortisone group and 25 (17) days in the placebo group, with a mean absolute reduction in the hydrocortisone group of −8 days (95% CI, −13 to −3; P =.002; Table 2 ). No difference was observed regarding other infections, organ failure, or death rate (Table 2) . On day 8, 25 of 40 patients (62.5%) in the hydrocortisone group vs 17 of 51 (33.3%) in the placebo group continued to have corticosteroid insufficiency, with a mean absolute difference in the hydrocortisone group of 29% (95% CI, 9% to 49%; P Ͻ .001; Table 2 ).
For the entire study population, 6 of 73 patients (8.2%) died in the hydrocortisone group and 4 of 76 (5.3%) died in the placebo group, with a mean absolute difference of 3% (95% CI, −5% to 11%; P =.44; see eTable 3 for cause of deaths, available at http://www.jama .com). Six of 56 patients (10.7%) with corticosteroid insufficiency in the hydrocortisone group and 3 of 57 (5.3%) in placebo group died, with a mean absolute difference of 5% (95% CI, −5% to 15%; P=.23, see eTable 3). Seven of 76 patients (9.2%) in the placebo group and none of the 73 in the hydrocortisone group developed hyponatremia, with a mean absolute difference of −9% (95% CI, −16% to −3%; P=.01; Table 2 ). One patient (1.4%) in the hydrocortisone group who had abdominal trauma, and none in the placebo group developed an ileum perforation with gastrointestinal bleeding.
COMMENT
This study shows that hydrocortisone treatment reduced the occurrence of hospital-acquired pneumonia within 28 days in trauma patients.
Hydrocortisone may prevent hospital-acquired pneumonia at the cellular level. At stress doses, corticosteroids have been shown to increase neutrophil activity, 9 increase the homing of dendritic cells with preservation of monocyte function, 23 preserve interleukin 12 function, and attenuate the overwhelming inflammatory response 10 that leads to sepsis in trauma patients. 14, 24, 25 The diagnosis of hospital-acquired pneumonia is difficult in the ICU, and we used previously described 3, 19, 20 and recommended 18 criteria. Trauma is a major risk factor for hospital-acquired pneumonia 26 ; the high rates of hospitalacquired pneumonia currently reported have already been described in patients experiencing severe trauma, notably patients with TBI. [2] [3] [4] Moreover, the reductions of mechanical ventilation duration as well as acute respiratory distress syndome incidence in the hydrocortisone group emphasize the clinical relevance of the current treatment. 27 Finally, it has already been reported that corticosteroid treatment leads to a reduction of nosocomial pneumonia in patients with acute respiratory distress syndome.
Randomization After Significant Head Injury (CRASH) study 28 in which corticosteroid therapy increased the risk of death in patients with TBI without modifying the incidence of pneumonia. In the CRASH study, a high dose of methylprednisolone for a short duration (2 days) was used in patients without corticosteroid function assessment.
As previously described, 5, 29, 30 we report a low mortality rate with no statistical difference between groups. However, there was a 2-fold higher mortality rate in the steroid-treated group. Two patients treated with hydrocortisone but no patient treated with placebo died during the first 48 hours from intracranial hypertension or refractory hemorrhage, the main causes of early death after trauma. 5, 29, 30 Regarding the mortality rate after 48 hours, 4 of 56 patients (7.1%) in the hydrocortisone group and 3 of 57 patients (5.3%) in the placebo group died (eTable 3 available at http://www.jama.com). Finally, considering mortality in the composite outcome did not modify the primary outcome results.
Among patients with corticosteroid insufficiency, norepinephrine was withdrawn earlier in the hydrocortisone group than in the placebo group. Indeed, hydrocortisone raises blood volume, increases vascular tone, enhances endothelial reactivity to vasopressors, 21 and reduces time-to-shock reversal. 6, 31 Etomidate may inhibit the metabolism of corticosteroids for 24 hours, 32 but the clinical consequences of etomidate-induced corticosteroid insufficiency remain controversial. 33 In our study, a single bolus of etomidate increased the risk of corticosteroid insufficiency, and the differences between groups remained significant when the analysis was adjusted for etomidate.
Some considerations should be emphasized. First, the higher rate of corticosteroid insufficiency on day 8 in the treatment group advocates for a slower tapering of hydrocortisone infusion. Moreover, the persistence of corticosteroid insufficiency in both groups suggests that hydrocortisone should be administered for a longer period. Second, the selection of patients likely to benefit from treatment with hydrocortisone is of particular interest. It has been argued that the measurement of free cortisol is more accurate than total cortisol, 34 but no clear cutoff are currently available in clinical practice. 7 Finally, 15% of patients would not have a corticosteroid insufficiency if the current definition of the consensus statement 7 was used; further studies are warranted to confirm the accuracy of the corticosteroid insufficiency definition in trauma patients.
In conclusion, a stress dose of hydrocortisone for 7 days is associated with a reduction in the rate of hospitalacquired pneumonia at day 28 together with a decreased requirement for mechanical ventilation and length of ICU stay in trauma patients. The effects and safety of corticosteroid therapy with stress-dose levels of hydrocortisone should be confirmed in trauma patients and investigated in other ICU populations, particularly in TBI patients.
